54 related articles for article (PubMed ID: 38521933)
21. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Louis DN; Perry A; Wesseling P; Brat DJ; Cree IA; Figarella-Branger D; Hawkins C; Ng HK; Pfister SM; Reifenberger G; Soffietti R; von Deimling A; Ellison DW
Neuro Oncol; 2021 Aug; 23(8):1231-1251. PubMed ID: 34185076
[TBL] [Abstract][Full Text] [Related]
22. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC
Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593
[TBL] [Abstract][Full Text] [Related]
23. The Effects of O
Yildiz OG; Aslan D; Akalin H; Erdem Y; Canoz O; Aytekin A; Ozoner S; Dundar M
Balkan J Med Genet; 2020 Jun; 23(1):33-41. PubMed ID: 32953407
[TBL] [Abstract][Full Text] [Related]
24. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
[TBL] [Abstract][Full Text] [Related]
25. Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
Chai RC; Zhang KN; Liu YQ; Wu F; Zhao Z; Wang KY; Jiang T; Wang YZ
CNS Neurosci Ther; 2019 Mar; 25(3):314-322. PubMed ID: 30117294
[TBL] [Abstract][Full Text] [Related]
26. Repair gene O
Aasland D; Reich TR; Tomicic MT; Switzeny OJ; Kaina B; Christmann M
J Neurochem; 2018 Jan; 144(2):139-151. PubMed ID: 29164620
[TBL] [Abstract][Full Text] [Related]
27. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.
Szopa W; Burley TA; Kramer-Marek G; Kaspera W
Biomed Res Int; 2017; 2017():8013575. PubMed ID: 28316990
[TBL] [Abstract][Full Text] [Related]
29. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
30. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.
Molenaar RJ; Verbaan D; Lamba S; Zanon C; Jeuken JW; Boots-Sprenger SH; Wesseling P; Hulsebos TJ; Troost D; van Tilborg AA; Leenstra S; Vandertop WP; Bardelli A; van Noorden CJ; Bleeker FE
Neuro Oncol; 2014 Sep; 16(9):1263-73. PubMed ID: 24510240
[TBL] [Abstract][Full Text] [Related]
31. Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.
Quillien V; Lavenu A; Sanson M; Legrain M; Dubus P; Karayan-Tapon L; Mosser J; Ichimura K; Figarella-Branger D
J Neurooncol; 2014 Feb; 116(3):487-96. PubMed ID: 24420923
[TBL] [Abstract][Full Text] [Related]
32. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
Bady P; Sciuscio D; Diserens AC; Bloch J; van den Bent MJ; Marosi C; Dietrich PY; Weller M; Mariani L; Heppner FL; Mcdonald DR; Lacombe D; Stupp R; Delorenzi M; Hegi ME
Acta Neuropathol; 2012 Oct; 124(4):547-60. PubMed ID: 22810491
[TBL] [Abstract][Full Text] [Related]
33. O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.
Silber JR; Bobola MS; Blank A; Chamberlain MC
Biochim Biophys Acta; 2012 Aug; 1826(1):71-82. PubMed ID: 22244911
[TBL] [Abstract][Full Text] [Related]
34. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
Malley DS; Hamoudi RA; Kocialkowski S; Pearson DM; Collins VP; Ichimura K
Acta Neuropathol; 2011 May; 121(5):651-61. PubMed ID: 21287394
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM.
Shah N; Lin B; Sibenaller Z; Ryken T; Lee H; Yoon JG; Rostad S; Foltz G
PLoS One; 2011 Jan; 6(1):e16146. PubMed ID: 21249131
[TBL] [Abstract][Full Text] [Related]
36. [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].
Wick W; Weller M
Nervenarzt; 2010 Aug; 81(8):928-30, 932-5. PubMed ID: 20635074
[TBL] [Abstract][Full Text] [Related]
37. Prediction of CpG-island function: CpG clustering vs. sliding-window methods.
Hackenberg M; Barturen G; Carpena P; Luque-Escamilla PL; Previti C; Oliver JL
BMC Genomics; 2010 May; 11():327. PubMed ID: 20500903
[TBL] [Abstract][Full Text] [Related]
38. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
Rivera AL; Pelloski CE; Gilbert MR; Colman H; De La Cruz C; Sulman EP; Bekele BN; Aldape KD
Neuro Oncol; 2010 Feb; 12(2):116-21. PubMed ID: 20150378
[TBL] [Abstract][Full Text] [Related]
39. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.
Everhard S; Tost J; El Abdalaoui H; Crinière E; Busato F; Marie Y; Gut IG; Sanson M; Mokhtari K; Laigle-Donadey F; Hoang-Xuan K; Delattre JY; Thillet J
Neuro Oncol; 2009 Aug; 11(4):348-56. PubMed ID: 19224763
[TBL] [Abstract][Full Text] [Related]
40. MGMT: its role in cancer aetiology and cancer therapeutics.
Gerson SL
Nat Rev Cancer; 2004 Apr; 4(4):296-307. PubMed ID: 15057289
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
